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Introduction 
Keratoacanthomas (KAs) are rapidly growing 
neoplasms of the squamous epithelium that are 
cosmetically disfiguring and difficult to distinguish 
clinically from squamous cell carcinoma (SCC). With 
a solitary KA, excisional biopsy can be quickly 
performed and has the benefit of being both 
diagnostic and curative. In cases of widespread KA 
eruption however, non-operative modalities may be 
better suited. This consideration is amplified when 
KAs have recurred following excision. Intralesional 5-
fluorouracil (5-FU) has been previously described in 
two patients who developed multiple KAs that 
would have been difficult to resect surgically [1, 2]. In 
both instances, weekly 5-FU injections led to 
resolution. Despite this success, having a patient 
return weekly is inconvenient and may not be 
necessary if less frequent treatments are also 
effective. We report a patient with multiple eruptive 
KAs, which failed previous excision but were 
successfully treated with intralesional 5-FU injections 
every three to four weeks. 
 
Case Synopsis 
A 68-year-old man with no significant past medical 
history presented to our clinic with an exophytic red 
papule with a central erosion on the right forearm, 
which had been present for two weeks. On the initial 
visit the lesion was removed via shave biopsy and 
pathology returned consistent with well-
differentiated KA. The lesion recurred and was 
excised 8 weeks after initial biopsy using an elliptical 
incision with deep and superficial sutures. The 
patient returned two weeks later with an eruption 
clinically consistent with multiple KAs surrounding 
the excision site (Figure 1A). Considering the 
reoccurrence and patient reluctance to undergo a 
second excision, the decision at that time was to 
inject 5-FU into the lesions and have the patient 
return in three weeks. At this return visit there was 
obvious clinical improvement and the patient was 
satisfied with the results and interested in continuing  
Abstract 
Keratoacanthomas are rapidly growing neoplasms of 
squamous epithelium. Despite their benign nature, 
they are often difficult to distinguish from squamous 
cell carcinoma and require excision. In cases in which 
excision is not successful or not desired, intralesional 
treatments may be considered. However, limited 
research exists on individual therapeutic efficacy. We 
present a 68-year-old man who developed multiple 
eruptive keratoacanthomas around the wound edge 
of a previous keratoacanthoma excision. Considering 
previous excisional failure, intralesional 5-
fluorouracil was used as a treatment modality. 
Injections every 3-4 weeks over a course of 12 weeks 
induced clinical keratoacanthoma clearance with 
excellent cosmetic results. This case showcases that 
weekly intralesional 5-fluorouracil injections, as was 
the standard mode of treatment in previous case 
reports, may not be necessary. This less frequent 
injection strategy is more convenient for the patient 
and may lead to fewer treatments and less 
medication necessary. Although a case-by-case basis 
is needed for any alternative approach to 
keratoacanthoma treatment, this report is useful for 
the practicing clinician in showing that 5-fluorouracil 
may be efficacious in these difficult-to-treat patients. 
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treatment (Figure 1B). The patient was 
subsequently injected at this visit and three 
additional visits before there was clinical resolution 
of the KA with minimal scarring (Figure 1C). A total 
of 5ml of 5-FU was injected into the base of the KAs. 
There were no associated adverse events and the 
patient tolerated the injections well. Given clinical 
resolution, a confirmatory biopsy was not performed 
at this time and the lesions were instead monitored 
with follow up appointments. At a 10-month follow 
up the site remained clear without KA recurrence 
and with excellent cosmetic outcome. 
 
Case Discussion 
In this instance, the predisposition for developing 
KAs at excisional sites necessitated an alternative 
approach. We were able to achieve KA resolution 
with excellent cosmetic results following 5-FU 
injections at three to four-week intervals. Our 
approach was rooted in the recognition that 
although some studies reported clinical 
improvement one week following a 5-FU injection, 
others did not [3]. Given 5-FU’s mechanism of action 
by inhibiting DNA synthesis, it is likely that one week 
is not an adequate time to quantify the full impact on 
KA destruction that each injection would have. By 
spacing these injections out by several weeks, we 
could visualize the final outcome of each treatment 
and reduce the number of treatments (and overall 5-
FU) necessary for resolution. Fortunately, there have 
been no reports of systemic adverse events 
following intralesional 5-FU. Nonetheless, if the  
lesion can be cleared successfully with less frequent 
injections this could save patient and provider time 
and reduce the risk of potential side effects. 
It is unclear what causes recurrent KAs at excisional 
sites. However, they are sparsely described in the 
literature. The addition of oral acitretin to 
intralesional 5-FU has also been successful in more 
widespread cases of KAs [4]. The side effect profile of 
oral retinoid-based medications may preclude 
extensive use but this may be an option to consider 
in cases which do not resolve with intralesional 5-FU 
treatment alone. Similarly, topical 5-FU is commonly 
used for actinic keratosis, another potentially 
malignant lesion of keratinocytes, and may be useful 
for smaller KAs if the patient does not wish to 
undergo intralesional injections [5]. 
 
Conclusion 
We report a unique case of recurrent KAs, which were 
refractory to excision and subsequently treated with 
5-FU injections. For the practicing clinician, this 
report serves to showcase that eruptive KAs can 
recur surrounding an excisional site and that 
intralesional 5-FU at three to four-week intervals can 
achieve complete resolution with excellent cosmetic 
outcomes. 
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Figure 1. Treatment of eruptive keratoacanthomas with intralesional 5-fluorouracil. A) Eruptive keratoacanthomas on right forearm on 
day 0 prior to treatment with intralesional 5-fluorouracil. B) 70% improvement three weeks after first injection. C) Final outcome 
following five injections over 12 weeks. 
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